What type of study is this?

December 8, 2025BloodOpen Access

Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis reveals venetoclax use in 1L and 2L+ treatment of CLL, indicating varying patient comorbidities.

Patients receiving venetoclax demonstrated varied comorbidities like anemia and leukopenia, affecting treatment outcomes.
In the first-line setting, 61.4% of patients received venetoclax plus obinutuzumab, with a median treatment duration of 15.2 months.
Assessment using electronic health records from 3 million oncology patients provided insights into treatment patterns.
Findings suggest potential implications for long-term follow-up due to extended therapy durations beyond recommended limits.

Aton et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis reveals venetoclax use in 1L and 2L+ treatment of CLL, indicating varying patient comorbidities.

Patients receiving venetoclax demonstrated varied comorbidities like anemia and leukopenia, affecting treatment outcomes.
In the first-line setting, 61.4% of patients received venetoclax plus obinutuzumab, with a median treatment duration of 15.2 months.
Assessment using electronic health records from 3 million oncology patients provided insights into treatment patterns.
Findings suggest potential implications for long-term follow-up due to extended therapy durations beyond recommended limits.

Aton et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark